JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY HYDERABAD Pharm. D V Year PHARMACOEPIDEMIOLOGY AND PHARMACOECONOMICS Previous Question Paper (October - 2020 - R08)

Pharmacoeconomics emerged as a distinct discipline in the late 20th century, driven by the escalating costs of healthcare and the need for evidence-based resource allocation. The term was formally coined by Ray Townsend in 1986, marking the transition from traditional clinical pharmacology to a focus on the economic value of pharmaceutical interventions.

The evaluation of pharmacoeconomics has progressed through several key stages:

1. Early Development: Initially, the field focused on simple cost-minimization studies, primarily comparing generic versus brand-name drugs to reduce expenditures.
2. Methodological Standardization: As the field matured, researchers developed standardized frameworks for cost-effectiveness analysis (CEA), cost-utility analysis (CUA), and cost-benefit analysis (CBA). This period saw the establishment of guidelines for conducting economic evaluations to ensure transparency and comparability.
3. Integration into Decision Making: Pharmacoeconomic data became a cornerstone for Health Technology Assessment (HTA) agencies, such as the UK's NICE, which utilize these evaluations to determine the reimbursement status and pricing of new medications based on their value-for-money.
4. Modern Scope: Today, the discipline encompasses real-world evidence (RWE), patient-reported outcomes (PROs), and budget impact analysis. It has shifted from purely clinical outcomes to a broader perspective that includes quality-adjusted life years (QALYs) and societal impacts.

The evaluation process itself relies on the ECHO model, which categorizes outcomes into Economic, Clinical, and Humanistic components. By systematically measuring these three domains, pharmacoeconomics provides a robust framework for balancing clinical efficacy with economic sustainability in modern healthcare systems.